PHARMAC performance 2016/17 Q3
Performance data to 31 March 2016/17
Output Class 1: Decision-making
Measure: All funding decisions are supported by evidence and made using PHARMAC’s decision-making approach.
Status: On track. All funding decisions supported by evidence and made using PHARMAC’s decision-making approach.
Measure: Decisions on more than 90% of line items (excluding bids held open while awaiting Medsafe registration) will be made within six months of the tender closing.
Status: On track. The tender closed on 15 December 2016 and we are continuing to work through the decisions.
Measure: Cumulative five year value to Vote Health at 30 June 2017 exceeds cumulative five year value of additional baseline contribution to PHARMAC’s operation.
Status: On track. Five-year cumulative value of all decisions since 2013/14 is $214.83 million across both hospital medicines and devices, well in excess of the five-year value of PHARMAC’s baseline funding.
Output Class 2: Influencing medicines use
Measure: At least half of all DHBs or agents will engage with PHARMAC on implementing hospital medical device national contracts.
All relevant DHB hospital services will engage with PHARMAC to support hospital medicine changes.
Status: On track. All DHBs have engaged with PHARMAC in transitioning to the wound care market share products.
PHARMAC has proactively engaged with, and received feedback from, hospital pharmacists and prescribers on the proposal to delist a strength of tramadol with potential safety concerns.
Measure: Surveys of attendees show at least 90% of surveyed attendees rate their satisfaction with the Seminars at least four out of five.
Status: On track. 93% of attendees at the 3 seminars between 1 January and 31 March 2017 rate their satisfaction with the seminars at least 4 out of 5.
Measure: Community-based delivery of HRPHOW programme occurs with at least 3 MoA partners.
Status: On track. WOC partner numbers have increased from six to eight, and six community-based programmes were delivered.
Measure: Respond to low medicine stock reports, communicate effectively and take action as necessary to ensure patient needs for medicines are met.
Status: On track. All stock reports are monitored and managed.
Output Class 3: Providing policy advice and support
Measure: An average survey score of at least 4.5 in each area.
Status: On track. This survey is completed annually at year-end and reported in the Annual Report.
Measure: All fund use is in accordance with PHARMAC policy.
Status: On track. Policy is adhered to.
Last updated: 3 May 2017